Filing Flows › Alamar Biosciences (ALMR) › Q2 2026 › vs Q1 2026
Alamar Biosciences (ALMR) Q2 2026 vs Q1 2026 (quarter over quarter)
Alamar Biosciences's revenue rose $3.4M (+13%) from $26.0M in Q1 2026 to $29.4M in Q2 2026. The biggest changes: Product +$1.9M (+9%); Service Other +$1.5M (+31%).
Alamar Biosciences, Q2 2026: revenue $29.4M (+82% year over year), operating margin -46.0%, net loss $13.2M, operating cash flow −$11.3M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Consumables | $15.5M | $14.0M | $1.5M | +11% |
| Instruments | $7.8M | $7.4M | $407K | +6% |
| Product | $23.3M | $21.3M | $1.9M | +9% |
| Service Other | $6.2M | $4.7M | $1.5M | +31% |
| Revenue | $29.4M | $26.0M | $3.4M | +13% |
| Other income, net | $240K | −$8.5M | $8.8M | — |
| Income tax benefit | $93K | −$464K | $557K | — |
| Net loss | $13.2M | $21.3M | −$8.1M | -38% |
| Costs & expenses | $43.0M | $47.4M | −$4.4M | -9% |
| Operating costs | $43.0M | $38.4M | $4.6M | +12% |
| Cost of revenue | $11.7M | $11.6M | $131K | +1% |
| Research & development | $13.8M | $13.0M | $800K | +6% |
| SG&A | $17.4M | $13.8M | $3.6M | +26% |
| Operating cash sources | $15.7M | $23.0M | −$7.2M | -32% |
| Depreciation & amortization | $1.1M | $1.2M | −$33K | -3% |
| Share-based compensation | $3.3M | $1.5M | $1.8M | +124% |
| Cash used in operations | $11.3M | $20.3M | −$9.0M | -44% |
| Net loss absorbed | $13.2M | $21.3M | −$8.1M | -38% |
| Working capital & other | $2.5M | $1.7M | $881K | +53% |
Questions
How much did Alamar Biosciences's revenue grow quarter over quarter in Q2 2026?
Alamar Biosciences's revenue rose $3.4M (+13%) from $26.0M in Q1 2026 to $29.4M in Q2 2026.
What drove Alamar Biosciences's revenue change in Q2 2026?
Product +$1.9M (+9%); Service Other +$1.5M (+31%).